Anna Bratulic is a journalist with a focus on the pharmaceutical and biotech industries. She covers a wide range of topics, including drug development, clinical trials, regulatory updates, and business news. Anna has a keen interest in providing accurate and up-to-date information to readers in the healthcare and life sciences sectors.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Anna's coverage primarily focuses on the healthcare and pharmaceutical industry, particularly drug development, clinical trials, and FDA approvals. Her articles heavily feature press releases and cited data.
Given Anna’s focus on private sector announcements and reliance on data, she is likely to be responsive to pitches offering insights from professionals within the pharmaceutical industry who can provide in-depth analysis of new drugs or treatments. Pitches should highlight concrete data or exclusive details related to drug development processes, clinical trial results, or regulatory approvals.
While no specific geographic focus is mentioned for Anna's reporting, her topics cover international pharmaceutical developments rather than a localized perspective.
This information evolves through artificial intelligence and human feedback. Improve this profile .
NewAmsterdam Pharma's experimental cholesterol drug obicetrapib has cleared another hurdle, delivering positive results in its third consecutive
Eli Lilly is looking to expand the arsenal of treatments for ER+/HER2- advanced breast cancer, unveiling new data at the San Antonio Breast Cancer
By: Anna Bratulic
Biotech startup nChroma Bio made its debut Wednesday following the merger of Chroma Medicine and Nvelop Therapeutics, securing $75 million in
Amid fierce competition in the atopic dermatitis landscape, AnaptysBio's BTLA-targeting contender ANB032 was a bit of a long shot.
Investors sold off Q32 Bio shares in large numbers Wednesday after a major setback for its experimental drug bempikibart (ADX-914), with the company's
Keros Therapeutics announced a voluntary suspension of dosing in two treatment arms of its Phase II TROPOS trial for cibotercept (KER-012), a
Corcept Therapeutics said its experimental drug dazucorilant did not meet the primary endpoint of slowing functional decline in a Phase II study of
By: Anna Bratulic
Having settled on the HER3-targeting antibody-drug conjugate (ADC) EO-1022 for further development, Elevation Oncology is now teaming up with Synaffix as it prepares to move the compound into clinical testing.
Fresh from stealth, Ottimo Pharma has secured $140 million in series A financing to propel its PD1/VEGFR2 bifunctional antibody programme toward clinical trials.
Gene therapy startup GEMMABio, which launched in October by industry veteran Jim Wilson , has secured $34 million in seed funding, building on its
(833) 317-6278 